Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 4
2007 6
2008 5
2009 1
2010 4
2011 6
2012 12
2013 11
2014 4
2015 5
2016 1
2017 3
2018 5
2019 4
2020 7
2021 4
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: schiavon g. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Howell SJ, et al. Among authors: schiavon g. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. Lancet Oncol. 2022. PMID: 35671774 Free PMC article. Clinical Trial.
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Garcia-Murillas I, et al. Among authors: schiavon g. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021. Sci Transl Med. 2015. PMID: 26311728
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Pass M, Rowlands V, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Smyth LM, et al. Among authors: schiavon g. Clin Cancer Res. 2020 Aug 1;26(15):3947-3957. doi: 10.1158/1078-0432.CCR-19-3953. Epub 2020 Apr 20. Clin Cancer Res. 2020. PMID: 32312891 Free PMC article. Clinical Trial.
A View on Drug Development for Cancer Prevention.
Reynolds AR, Moschetta M, Yohannes AR, Walcott F, Ashford M, Szucs Z, Sarbajna T, Hadfield J, Harrison E, Challis BG, Hernandez AG, Schiavon G, Germa C, Zorenyi G, Crean B, Galbraith S. Reynolds AR, et al. Among authors: schiavon g. Cancer Discov. 2023 May 4;13(5):1058-1083. doi: 10.1158/2159-8290.CD-22-0776. Cancer Discov. 2023. PMID: 37067191 Review.
The biological properties of cetuximab.
Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. Vincenzi B, et al. Among authors: schiavon g. Crit Rev Oncol Hematol. 2008 Nov;68(2):93-106. doi: 10.1016/j.critrevonc.2008.07.006. Epub 2008 Aug 3. Crit Rev Oncol Hematol. 2008. PMID: 18676156 Review.
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK, Dolce EM, Darga EP, Hu K, Liu CJ, Pierce J, Bradbury K, Kilgour E, Aung K, Schiavon G, Carroll D, Carr TH, Klinowska T, Lindemann J, Marshall G, Rowlands V, Harrington EA, Barrett JC, Sathiyayogan N, Morrow C, Sero V, Armstrong AC, Baird R, Hamilton E, Im SA, Jhaveri K, Patel MR, Dive C, Tomlins SA, Udager AM, Hayes DF, Paoletti C. Cani AK, et al. Among authors: schiavon g. Mol Oncol. 2022 May;16(10):1969-1985. doi: 10.1002/1878-0261.13150. Epub 2021 Dec 20. Mol Oncol. 2022. PMID: 34866317 Free PMC article.
Drug transporters and imatinib treatment: implications for clinical practice.
Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH. Eechoute K, et al. Among authors: schiavon g. Clin Cancer Res. 2011 Feb 1;17(3):406-15. doi: 10.1158/1078-0432.CCR-10-2250. Epub 2010 Dec 16. Clin Cancer Res. 2011. PMID: 21163869 Review.
79 results